

Inclusion Criteria

8. Participant has adequate organ function as indicated by laboratory values (If a participant has received a recent blood transfusion, the laboratory tests must be obtained \geq 14 days after any blood transfusion.)

9. Female participant:

- Is not pregnant and at least one of the following conditions apply:

o Not a woman of childbearing potential (WOCBP)

o WOCBP who has a negative serum pregnancy test and confirmed not pregnant by medical interview at screening and agrees to follow the contraceptive guidance from the time of informed consent through 7 months after final study intervention administration.

- Must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 7 months after the final study intervention administration.

- Must not donate ova starting at first administration of study intervention and throughout the investigational period and for 7 months after final study intervention administration.

10. Male participant:

- Must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period and for 4 months after final study intervention administration.

- Must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 4 months after final study intervention administration.

- Must not donate sperm during the treatment period and for 4 months after final study intervention administration.

11. Participant agrees not to participate in another interventional study while receiving study intervention in the present study/participating in the present study (participant who is currently in the follow-up period of an interventional clinical study is allowed).

Exclusion Criteria

29. Participant has any condition that makes the participant unsuitable for study participation.

30. Participant has a known or suspected hypersensitivity to study intervention or any components of the formulation used.

31. Participant has history of life-threatening (anaphylaxis) hypersensitivity reactions to monoclonal antibodies, bispecifics, immunomodulatory drugs or antibody-drug conjugates (ADCs).